Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dry powder inhalation preparation of expectorant and preparation method of dry powder inhalation preparation

A dry powder inhalation and preparation technology, which is applied in the direction of medical formulas, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve the problems of no expectorant preparations, etc., and achieve the effect of increasing secretion

Active Publication Date: 2022-01-14
苏州易合医药有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Despite extensive research, there are currently no clinically available expectorant preparations for inhalation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry powder inhalation preparation of expectorant and preparation method of dry powder inhalation preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] The dry powder inhalation preparation for eliminating phlegm in this embodiment includes the following raw materials: active pharmaceutical components, carriers and excipients;

[0052] The mass percentage of the active pharmaceutical component in the total amount is 80%, the mass percentage of the carrier in the total amount is 10%, and the mass percentage of the adjuvant in the total amount of raw materials is 10%.

[0053] Wherein said active drug component is ambroxol, acetylcysteine, the mass ratio between the two is 1:10;

[0054] The carrier is lactose;

[0055] The auxiliary materials mentioned therein are magnesium stearate, phospholipid, and leucine, and the mass ratio between the three is 0.1:1:0.5.

[0056] In the above-mentioned dry powder inhalation preparation for expectorant,

[0057] The particle size range of the active pharmaceutical component is 0.5um-5um.

[0058] In the above-mentioned dry powder inhalation preparation for expectorant,

[0059]...

Embodiment 2

[0070] The dry powder inhalation preparation for eliminating phlegm in this embodiment includes the following raw materials: active pharmaceutical components, carriers and excipients;

[0071] The mass percentage of the active pharmaceutical component in the total amount is 80%, the mass percentage of the carrier in the total amount is 10%, and the mass percentage of the adjuvant in the total amount of raw materials is 10%.

[0072] Wherein said active drug component is ambroxol, acetylcysteine, the mass ratio between the two is 1:5;

[0073] The carrier is lactose;

[0074] The auxiliary materials mentioned therein are magnesium stearate, phospholipid, and leucine, and the mass ratio between the three is 0.1:1:0.5.

[0075] In the above-mentioned dry powder inhalation preparation for expectorant,

[0076] The particle size range of the active pharmaceutical component is 0.5um-5um.

[0077] In the above-mentioned dry powder inhalation preparation for expectorant,

[0078] ...

Embodiment 3

[0089] The dry powder inhalation preparation for eliminating phlegm in this embodiment includes the following raw materials: active pharmaceutical components, carriers and excipients;

[0090] The mass percentage of the active pharmaceutical component in the total amount is 80%, the mass percentage of the carrier in the total amount is 10%, and the mass percentage of the adjuvant in the total amount of raw materials is 10%.

[0091] Wherein said active drug component is ambroxol, acetylcysteine, the mass ratio between the two is 1:2;

[0092] The carrier is lactose;

[0093] The auxiliary materials mentioned therein are magnesium stearate, phospholipid, and leucine, and the mass ratio between the three is 0.1:1:0.5.

[0094] In the above-mentioned dry powder inhalation preparation for expectorant,

[0095] The particle size range of the active pharmaceutical component is 0.5um-5um.

[0096] In the above-mentioned dry powder inhalation preparation for expectorant,

[0097] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a dry powder inhalation preparation of an expectorant and a preparation method of the dry powder inhalation preparation, and belongs to the technical field of dry powder inhalation preparations. The dry powder inhalation preparation comprises the following raw materials of an active drug component, a carrier and an auxiliary material, wherein the mass percentage of the active drug component in the total amount is 0.1%-99.9%, the mass percentage of the carrier in the total amount is 0%-99.9%, and the mass percentage of the auxiliary material in the total amount of the raw materials is 0%-10%; the active drug component is one or two of ammonium chloride, potassium iodide, bromhexine, ambroxol, acetylcysteine, carbocisteine and tiloxpol; the carrier is lactose; and the auxiliary material is one or more of magnesium stearate, phospholipid, leucine and lysine. The prepared dry powder inhalation preparation of the expectorant can effectively improve the secretion amount of phenol red in the trachea of mice.

Description

technical field [0001] The invention belongs to the technical field of dry powder inhalation preparations, and in particular relates to a dry powder inhalation preparation of an expectorant and a preparation method thereof. Background technique [0002] Phlegm is the product of respiratory inflammation, which can irritate the mucous membrane of the respiratory tract, cause coughing, and aggravate infection. Expectorants can change the viscous components in sputum, reduce the viscosity of sputum, and make sputum easy to cough up. [0003] Expectorants can be divided into three categories according to their mode of action: [0004] 1. Nauseous and irritating expectorants: such as ammonium chloride and guaifenesin are nauseating expectorants, which can stimulate the gastric mucosa after oral administration, causing mild nausea and reflexively increasing the secretion of respiratory glands. So as to dilute the mucus and make it easy to cough up; stimulating expectorants are so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/72A61K9/14A61K47/26A61K31/198A61K31/137A61P11/10
CPCA61K9/145A61K9/0073A61K31/198A61K31/137A61P11/10A61K2300/00
Inventor 张庆珍史楷岐叶雨晴马颖亮祝京旭
Owner 苏州易合医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com